{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study.","timeFrame":"Baseline to the end of the study (up to 7 years, 7 months)","title":"Percentage of Participants Who Withdrew From Treatment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}